NCT05263050: Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- State
- Under way
- Phase
- Phase 2
- People
- 111 planned
- Started
- 21 Jan 2022
- Primary completion
- Dec 2026
- Arms
- Cabozantinib and nivolumab
- Results
- None posted
- 21 Jan 2022: Trial started
- 2 Mar 2022: Trial registered